GRAL
GRAIL, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$80.34
−0.35%Aug 13, 2026, 07:36 UTC
Bank of America Corp DE increased its stake in GRAIL, Inc. by 29.0% during the quarter, purchasing an additional 205,611 shares, according to its Form 13F filing.
Source:Aug 10, 2026, 17:30 UTC
The FDA's Molecular and Clinical Genetics Panel is scheduled to evaluate GRAIL Inc.'s Premarket Approval Application for its multi-cancer early detection test.
Source:Aug 7, 2026, 15:26 UTC
Grail announced on Friday that the U.S. FDA plans to hold an advisory committee meeting in September to review its multi-cancer screening test Galleri, causing its shares to rise 4% in morning trade.
Source:Aug 5, 2026, 20:02 UTC
GRAIL, Inc. reported its second quarter 2026 financial results, with Galleri test volume increasing 35% year-over-year to more than 61,000 and Galleri revenue growing 24% to $42.6 million.
Jul 24, 2026, 10:36 UTC
A class action lawsuit was filed against GRAIL, Inc. and its senior executives for securities fraud related to misrepresentations about trial results.
Jul 16, 2026, 13:00 UTC
GRAIL announced a collaboration with Priority Health to offer the Galleri multi-cancer early detection test to Priority Health's self-insured employer groups.
Source:Jun 25, 2026, 13:00 UTC
GRAIL completed a $110 million equity financing with Samsung affiliates.
Source:Jun 22, 2026, 21:57 UTC
A securities class action lawsuit has been filed against Grail, Inc. and its executives, with a lead plaintiff deadline of August 4, 2026.
Source:Jun 16, 2026, 23:00 UTC
A class action lawsuit was filed against Grail, Inc. alleging securities fraud for misleading investors about NHS-Galleri's potential to reduce late-stage cancers.
Jun 5, 2026, 21:53 UTC
A class action lawsuit was filed against Grail, Inc. on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026.
Source:Jun 1, 2026, 01:04 UTC
GRAIL presented new data at the American Society of Clinical Oncology annual meeting showing its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses.
Source:Jun 1, 2026, 00:00 UTC
Joshua Ofman was appointed Chief Executive Officer of GRAIL, Inc., effective June 1, 2026, with a base salary of $800,000 and an equity grant of RSUs valued at $2,000,000 vesting over four years.